

AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior claims submitted in the application.

1-13. (Cancelled).

14. (Currently amended) A monoclonal antibody which is free-end specific for the free N-terminus of an amyloid β -peptide or a free C-terminus of amyloid β peptide A β 1-40, which antibody binds to said free N-terminus or said free C-terminus of soluble amyloid peptide and does not bind to the amyloid β -precursor protein from which said amyloid β -peptide may be proteolytically derived.

15-22. (Cancelled)

23. (Currently amended) [[A]] The monoclonal antibody of claim 14 wherein said antibody is a single chain antibody, which is free-end specific for the free N-terminus or free C-terminus of an amyloid β -peptide, which antibody does not bind to the amyloid β -precursor protein which said amyloid β -peptide may be proteolytically derived.

24. (Currently amended) ~~A single chain~~ The monoclonal antibody of claim 14 wherein said antibody in accordance with claim 23, which is free-end specific for the free N-terminus of an amyloid β -peptide.

25-32. (Cancelled)

33. (Currently amended) [[A]] The monoclonal antibody of in accordance with claim 14 wherein said antibody , which is free-end specific for the free C-terminus of the amyloid β -peptide A β 1-40, which antibody does not bind to the amyloid β -precursor protein which said amyloid β -peptide may be proteolytically derived.

34. (Cancelled)

35. (Previously presented) A single chain antibody in accordance with claim 24, which is free-end specific for the free N-terminus of amyloid β -peptide A β 1-40, A β 1-42 or A β 1-43.

36-37. (Cancelled)